Mintz represented the US Department of Energy in the closing of two separate loans totaling up to approximately $5.1 billion ...

Mintz represented the US Department of Energy in the closing of two separate loan guarantees totaling up to approximately ...

Benchmark Litigation has recognized 23 Mintz attorneys in its 2026 guide to the leading litigation firms and lawyers in the ...

The Inflation Reduction Act (IRA) continues to reshape the US drug‑pricing landscape as federal implementation accelerates and market responses evolve. In 2025, regulators advanced core IRA programs ...

Michael Renaud, Chair of Mintz’s Intellectual Property Division, has been named to IAM Global Leaders 2027, a guide ...

Mintz’s Managed Care, PBMs & Pharmacies practice is pleased to present a combined Summer / Fall 2025 PBM Policy and Legislative Update. This edition builds upon prior issues and summarizes activity ...

Welcome to FDA in Flux — A Mintz newsletter tracking rapid changes in policy and agency actions that impact medical, life sciences, and consumer product investment decisions and development strategies ...

Alex regularly represents issuers, underwriters, sponsors, investors, and investment banks in cross-border financings and ...

The first week of October 2025 marked a significant shift in U.S. drug pricing policy as the Trump administration unveiled a series of sweeping actions to deliver on his promise to lower drug prices.

Mintz advised the placement agents in connection with First Tracks Biotherapeutics’ $200 million private placement of common ...

Mintz advised Rocket Software on its acquisition of Geniez AI, a generative AI company specializing in mainframe technology.

Since May, the Trump administration has used tariffs and Most Favored Nation (MFN) drug pricing threats as a means to pressure pharmaceutical manufacturers to lower drug prices in the U.S. This ...